Abstract

Research Article

Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma

Susanne Koeppen*, Jörg Hense, Kay Wilhelm Nolte and Joachim Weis

Published: 03 January, 2022 | Volume 6 - Issue 1 | Pages: 001-004

Treatment options in multiple myeloma (MM) based on novel agents are often limited by dose-related neurotoxicity. Bortezomib, a highly active reversible proteasome inhibitor, frequently causes peripheral neuropathy (PN). Bortezomib-induced PN (BIPN) is characterized by a length-dependent, sensory, axonal polyneuropathy (PNP) with predominant small fiber-affection. Following dose reduction or drug discontinuation, BIPN resolves within 3-4 months in the majority of patients. The pathophysiological mechanisms of BIPN are unclear. Rare cases of a severe demyelinating or mixed BIPN with prominent motor involvement have been attributed to autoimmune or inflammatory reactions. A case report, including nerve pathology, is presented of a 59-year-old man with stage III IgG-κ MM who was treated with bortezomib on the occurrence of progressive disease. After the fourth cycle, he developed a painful distal symmetric sensory PNP followed by gait instability and muscle weakness increasing over 3 months despite early cessation of bortezomib.
Neurological examination revealed a distal flaccid tetraparesis mainly of the lower limbs with sensory loss and severe ataxia, electrophysiological features of a mixed axonal-demyelinating PNP, and pathomorphological evidence of neuritis. Steroid treatment was initiated, and partial recovery of the neurological symptoms within 6 months was observed. While a neurotoxic effect may explain the initial distal sensory disturbances, the worsening of neurological dysfunction after bortezomib withdrawal and the clinical pattern with steroid-responsive muscle weakness predominantly of the legs are consistent with an immune-mediated mechanism. This is in line with the sural nerve biopsy findings. Toxic BIPN followed by an immune-mediated BIPN in the same patient has not been reported before.

Read Full Article HTML DOI: 10.29328/journal.apcr.1001028 Cite this Article Read Full Article PDF

Keywords:

Peripheral neuropathy; Immune mechanisms; Chemotherapy; Bortezomib; Multiple myeloma

References

  1. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and J Clin Oncol. 2009; 27: 3518-3525. PubMed: https://pubmed.ncbi.nlm.nih.gov/19528374/
  2. Meregalli An Overview of Bortezomib-Induced Neurotoxicity. Toxics. 2015; 3: 294-303. PubMed: https://pubmed.ncbi.nlm.nih.gov/29051465/
  3. Ale A, Bruna J, Calls A, Karamita M, Haralambous S, et al. Inhibition of the neuronal NFkappaB pathway attenuates bortezomib-induced neuropathy in a mouse Neurotoxicology. 2016; 55: 58-64. PubMed: https://pubmed.ncbi.nlm.nih.gov/27211850/
  4. Jeter A, Kang Y, Immune modulation therapy in the management of bortezomib-induced peripheral Exp Hematol Oncol. 2012; 1: 20. PubMed: https://pubmed.ncbi.nlm.nih.gov/23211009/
  5. Ale A, Bruna J, Navarro X, Udina E. Neurotoxicity induced by antineoplastic proteasome Neurotoxicology. 2014; 43: 28-35. PubMed: https://pubmed.ncbi.nlm.nih.gov/24525285/
  6. Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan 3rd Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. J Clin Neuromuscul Dis. 2015; 16: 202-209. PubMed: https://pubmed.ncbi.nlm.nih.gov/25996966/
  7. Lees JG, Makker PGS, Tonkin RS, Abdulla M, Park SB, et al. Immune-mediated processes implicated in chemotherapy-induced peripheral Eur J Cancer. 2017; 73: 22-29. PubMed: https://pubmed.ncbi.nlm.nih.gov/28104535/
  8. Staff NP, Podratz JL, Grassner L, Bader M, Paz J, et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion Neurotoxicology. 2013; 39: 124-131. PubMed: https://pubmed.ncbi.nlm.nih.gov/24035926/
  9. Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, et al. Follow-up psychophysical studies in bortezomib-related chemo neuropathy J Pain. 2011; 12: 1017-1024. PubMed: https://pubmed.ncbi.nlm.nih.gov/21703938/
  10. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification Br J Haematol. 2009; 144: 895-903. PubMed: https://pubmed.ncbi.nlm.nih.gov/19170677/
  11. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority Lancet Oncol. 2011; 12: 431-140. PubMed: https://pubmed.ncbi.nlm.nih.gov/21507715/
  12. Meregalli C, Marjanovic I, Scali C, Monza L, Spinoni N, et al. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. J 2018; 15: 232. PubMed: https://pubmed.ncbi.nlm.nih.gov/30131066/
  13. Xu YL, Zhao WH, Tang ZY, Li ZQ, Long Y, et al. Guillain-Barre syndrome in a patient with multiple myeloma after bortezomib therapy: A case World J Clin Cases. 2019; 7: 2905-2909. PubMed: https://pubmed.ncbi.nlm.nih.gov/31616710/
  14. Mauermann ML, Blumenreich MS, Dispenzieri A, Staff NP. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib Muscle Nerve. 2012; 46: 970-977. PubMed: https://pubmed.ncbi.nlm.nih.gov/23225391/
  15. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, et al. Immune-mediated neuropathies in myeloma patients treated with Clin Neurophysiol. 2008; 119: 2507-2512. PubMed: https://pubmed.ncbi.nlm.nih.gov/18829381/
  16. Saifee TA, Elliott KJ, Rabin N, Yong KL, D'Sa S, et al. Bortezomib-induced inflammatory J Peripher Nerv Syst. 2010; 15: 366-368. PubMed: https://pubmed.ncbi.nlm.nih.gov/21199108/
  17. Schmitt S, Goldschmidt H, Storch-Hagenlocher B, Pham M, Fingerle-Rowson G, et al. Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol. 2011; 93: 791-794. PubMed: https://pubmed.ncbi.nlm.nih.gov/21553020/ 

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

  • Synthesis of Carbon Nano Fiber from Organic Waste and Activation of its Surface Area
    Himanshu Narayan*, Brijesh Gaud, Amrita Singh and Sandesh Jaybhaye Himanshu Narayan*,Brijesh Gaud,Amrita Singh,Sandesh Jaybhaye. Synthesis of Carbon Nano Fiber from Organic Waste and Activation of its Surface Area. Int J Phys Res Appl. 2019: doi: 10.29328/journal.ijpra.1001017; 2: 056-059
  • Obesity Surgery in Spain
    Aniceto Baltasar* Aniceto Baltasar*. Obesity Surgery in Spain. New Insights Obes Gene Beyond. 2020: doi: 10.29328/journal.niogb.1001013; 4: 013-021
  • Tamsulosin and Dementia in old age: Is there any relationship?
    Irami Araújo-Filho*, Rebecca Renata Lapenda do Monte, Karina de Andrade Vidal Costa and Amália Cinthia Meneses Rêgo Irami Araújo-Filho*,Rebecca Renata Lapenda do Monte,Karina de Andrade Vidal Costa,Amália Cinthia Meneses Rêgo. Tamsulosin and Dementia in old age: Is there any relationship?. J Neurosci Neurol Disord. 2019: doi: 10.29328/journal.jnnd.1001025; 3: 145-147
  • Case Report: Intussusception in an Infant with Respiratory Syncytial Virus (RSV) Infection and Post-Operative Wound Dehiscence
    Lamin Makalo*, Orlianys Ruiz Perez, Benjamin Martin, Cherno S Jallow, Momodou Lamin Jobarteh, Alagie Baldeh, Abdul Malik Fye, Fatoumatta Jitteh and Isatou Bah Lamin Makalo*,Orlianys Ruiz Perez,Benjamin Martin,Cherno S Jallow,Momodou Lamin Jobarteh,Alagie Baldeh,Abdul Malik Fye,Fatoumatta Jitteh,Isatou Bah. Case Report: Intussusception in an Infant with Respiratory Syncytial Virus (RSV) Infection and Post-Operative Wound Dehiscence. J Community Med Health Solut. 2025: doi: 10.29328/journal.jcmhs.1001051; 6: 001-004
  • The prevalence and risk factors of chronic kidney disease among type 2 diabetes mellitus follow-up patients at Debre Berhan Referral Hospital, Central Ethiopia
    Getaneh Baye Mulu, Worku Misganew Kebede, Fetene Nigussie Tarekegn, Abayneh Shewangzaw Engida, Migbaru Endawoke Tiruye, Mulat Mossie Menalu, Yalew Mossie, Wubshet Teshome and Bantalem Tilaye Atinafu* Getaneh Baye Mulu,Worku Misganew Kebede,Fetene Nigussie Tarekegn,Abayneh Shewangzaw Engida,Migbaru Endawoke Tiruye,Mulat Mossie Menalu,Yalew Mossie,Wubshet Teshome,Bantalem Tilaye Atinafu*. The prevalence and risk factors of chronic kidney disease among type 2 diabetes mellitus follow-up patients at Debre Berhan Referral Hospital, Central Ethiopia. J Clini Nephrol. 2023: doi: 10.29328/journal.jcn.1001104; 7: 025-031

Read More

Most Viewed

Read More

Help ?